Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials

Philip S Helliwell,Chetan S Karyekar,Soumya D Chakravarty,Yin You,Kim Campbell,Shelly Kafka,Dafna D Gladman,Arthur Kavanaugh,Lianne S Gensler,Kristen Sweet

doi:10.1136/rmdopen-2019-001149

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials

Philip S Helliwell, Chetan S Karyekar + Show 8 more

Open Access

https://doi.org/10.1136/rmdopen-2019-001149

Copy DOI

Journal: RMD Open	Publication Date: Feb 1, 2020
Citations: 39	License type: open-access

Affiliation: Janssen (United States), Drexel University, NIHR Leeds Musculoskeletal Biomedical Research Unit, Krembil Foundation, University of Toronto, University of California, San Diego, University of California, San Francisco

#Psoriatic Arthritis Patients #Bath Ankylosing Spondylitis Disease Activity Index + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundThe interleukin-12/23p40-subunit-inhibitor ustekinumab significantly improved spondylitis-related symptoms through Week 24 in psoriatic arthritis (PsA) patients with peripheral arthritis and physician-reported spondylitis (PA-PRS) in PSUMMIT-1&2. We further evaluated ustekinumab’s effect on...

Full Text